Pierre robin sequence associated with first trimester fetal tamoxifen exposure

American Journal of Medical Genetics, Part A

Volumn 146, Issue 16, 2008, Pages 2141-2144

  Berger, Joel C ^a   Clericuzio, Carol L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cleft palate; Micrognathia; Pierre Robin sequence; Tamoxifen; Teratogen

Indexed keywords

GLIBENCLAMIDE; NORETHISTERONE; OXYTOCIN; RAMELTEON; TAMOXIFEN;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BREAST CANCER; CASE REPORT; CLEFT PALATE; CLUBFOOT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOFACIAL MALFORMATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FACE MALFORMATION; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GENETIC ANALYSIS; HUMAN; INTUBATION; MALE; MICROGNATHIA; PHYSICAL EXAMINATION; PIERRE ROBIN SYNDROME; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PRIORITY JOURNAL; RADIODIAGNOSIS; TRACHEOTOMY;

ABNORMALITIES, DRUG-INDUCED; BREAST NEOPLASMS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; PIERRE ROBIN SYNDROME; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; TAMOXIFEN;

ANIMALIA;

EID: 49449094617     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32432     Document Type: Article

References (12)

1. Barthelmes L, Gateley CA. 2004. Tamoxifen and pregnancy. Breast 13:446-451.
2. Brent RL. 1999. Utilization of developmental basic science principles in the evaluation of reproductive risks from preand postconception environmental radiation exposures. Teratology 59:182-204.
3. Cullins SL, Pridjian G, Sutherland CM. 1994. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. J Am Med Assoc 271:1905-1906.
4. Food and Drug Administration. 2007. AstraZeneca Pharmaceuticals. Nolvadex medication guide. Available at: http://www.fda.gov/cder/foi/label/2005/ 17970s053lbl.pdf. Accessed June 1.
5. Goldhirsch A, Gelber RD. 2004. Life with consequences of breast cancer: Pregnancy during and after endocrine therapies. Breast 13:443-445.
6. Howe LR. 2007. The biology behind rexinoids and breast cancer prevention. Clin Cancer Res 13:5983-5987.
7. Jones KL. 2005a. Smith's recognizable patterns of human malformation. 6th edition. Philadelphia: Elsevier Saunders. 262 p.
8. Jones KL. 2005b. Smith's recognizable patterns of human malformation. 6th edition. Philadelphia: Elsevier Saunders. 660 p.
9. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT, Richard JM, Sun SC. 1985. Retinoic acid embryopathy. N Engl J Med 313:837-841.
10. Oksuzoglu B, Guler N. 2002. An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 104:79.
11. Rutledge JC, Generoso WM. 1998. Reproductive and developmental toxicology. New York: Marcel Dekker. p 73-86.
12. Vieux-Rochas M, Coen L, Sato T, Kurihara Y, Gitton Y, Barbieri O, Le Blay K, Merlo G, Ekker M, Kurihara H, Janvier P, Levi G. 2007. Molecular dynamics of retinoic acid-induced craniofacial malformations: Implications for the origin of gnathostome jaws. PLoS ONE 2:e510.